CONTEXT: Symptom researchers have proposed a model of inflammatory cytokine activity and dysregulation in cancer to explain co-occurring symptoms including pain, fatigue, and sleep disturbance. OBJECTIVES: We tested the hypothesis that psychological stress accentuates inflammation and that stress and inflammation contribute to one's experience of the pain, fatigue, and sleep disturbance symptom cluster (symptom cluster severity, symptom cluster distress) and its impact (symptom cluster interference with daily life, quality of life). METHODS: We used baseline data from a symptom cluster management trial. Adult participants (N = 158) receiving chemotherapy for advanced cancer reported pain, fatigue, and sleep disturbance on enrollment. Before intervention, participants completed measures of demographics, perceived stress, symptom cluster severity, symptom cluster distress, symptom cluster interference with daily life, and quality of life and provided a blood sample for four inflammatory biomarkers (interleukin-1β, interleukin-6, tumor necrosis factor-α, and C-reactive protein). RESULTS: Stress was not directly related to any inflammatory biomarker. Stress and tumor necrosis factor-α were positively related to symptom cluster distress, although not symptom cluster severity. Tumor necrosis factor-α was indirectly related to symptom cluster interference with daily life, through its effect on symptom cluster distress. Stress was positively associated with symptom cluster interference with daily life and inversely with quality of life. Stress also had indirect effects on symptom cluster interference with daily life, through its effect on symptom cluster distress. CONCLUSION: The proposed inflammatory model of symptoms was partially supported. Investigators should test interventions that target stress as a contributing factor in co-occurring pain, fatigue, and sleep disturbance and explore other factors that may influence inflammatory biomarker levels within the context of an advanced cancer diagnosis and treatment.
RCT Entities:
CONTEXT: Symptom researchers have proposed a model of inflammatory cytokine activity and dysregulation in cancer to explain co-occurring symptoms including pain, fatigue, and sleep disturbance. OBJECTIVES: We tested the hypothesis that psychological stress accentuates inflammation and that stress and inflammation contribute to one's experience of the pain, fatigue, and sleep disturbance symptom cluster (symptom cluster severity, symptom cluster distress) and its impact (symptom cluster interference with daily life, quality of life). METHODS: We used baseline data from a symptom cluster management trial. Adult participants (N = 158) receiving chemotherapy for advanced cancer reported pain, fatigue, and sleep disturbance on enrollment. Before intervention, participants completed measures of demographics, perceived stress, symptom cluster severity, symptom cluster distress, symptom cluster interference with daily life, and quality of life and provided a blood sample for four inflammatory biomarkers (interleukin-1β, interleukin-6, tumor necrosis factor-α, and C-reactive protein). RESULTS: Stress was not directly related to any inflammatory biomarker. Stress and tumor necrosis factor-α were positively related to symptom cluster distress, although not symptom cluster severity. Tumor necrosis factor-α was indirectly related to symptom cluster interference with daily life, through its effect on symptom cluster distress. Stress was positively associated with symptom cluster interference with daily life and inversely with quality of life. Stress also had indirect effects on symptom cluster interference with daily life, through its effect on symptom cluster distress. CONCLUSION: The proposed inflammatory model of symptoms was partially supported. Investigators should test interventions that target stress as a contributing factor in co-occurring pain, fatigue, and sleep disturbance and explore other factors that may influence inflammatory biomarker levels within the context of an advanced cancer diagnosis and treatment.
Authors: Christine Miaskowski; Andrea Barsevick; Ann Berger; Rocco Casagrande; Patricia A Grady; Paul Jacobsen; Jean Kutner; Donald Patrick; Lani Zimmerman; Canhua Xiao; Martha Matocha; Sue Marden Journal: J Natl Cancer Inst Date: 2017-01-24 Impact factor: 13.506
Authors: Catherine Benedict; Jason R Dahn; Michael H Antoni; Lara Traeger; Bruce Kava; Natalie Bustillo; Eric S Zhou; Frank J Penedo Journal: Psychooncology Date: 2014-09-23 Impact factor: 3.894
Authors: Christian J Nelson; Christina Cho; Alexandra R Berk; Jimmie Holland; Andrew J Roth Journal: J Clin Oncol Date: 2009-12-07 Impact factor: 44.544
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Daniel L Hall; Inga T Lennes; William F Pirl; Emily R Friedman; Elyse R Park Journal: Support Care Cancer Date: 2016-12-13 Impact factor: 3.603
Authors: Kathleen Doyle Lyons; Marie Bakitas; Mark T Hegel; Brett Hanscom; Jay Hull; Tim A Ahles Journal: J Pain Symptom Manage Date: 2008-05-27 Impact factor: 3.612
Authors: Pei-Lin Yang; Robert L Burr; Diana T Buchanan; Kenneth C Pike; Kendra J Kamp; Margaret M Heitkemper Journal: J Clin Sleep Med Date: 2020-10-15 Impact factor: 4.062
Authors: Mellar P Davis; Lisa A Rybicki; Renato V Samala; Chirag Patel; Armida Parala-Metz; Ruth Lagman Journal: Support Care Cancer Date: 2021-01-21 Impact factor: 3.603
Authors: Joseph G Winger; Katherine Ramos; Karen E Steinhauser; Tamara J Somers; Laura S Porter; Arif H Kamal; William S Breitbart; Francis J Keefe Journal: Palliat Support Care Date: 2020-06
Authors: Hongjin Li; Tingting Liu; Lacey W Heinsberg; Mark B Lockwood; Derek A Wainwright; Min Kyeong Jang; Ardith Z Doorenbos Journal: Biol Res Nurs Date: 2020-06-30 Impact factor: 2.522